ARA-290

An 11-amino-acid peptide derived from erythropoietin's helix B, studied in trials for neuropathic pain in sarcoidosis.

What research shows

ARA-290 has genuine randomized human trials, all in sarcoidosis patients with small fibre neuropathy, where it improved symptom scores and corneal nerve measures. The populations were small and specific. Nothing we verified supports use for recovery, injury or performance in healthy people.

Evidence strength

Highest evidence grade among the graded claims: B. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.